– USA, CA – DexCom, Inc. (Nasdaq: DXCM) today announced that Richard Collins has been appointed to the company’s Board of Directors, effective March 9, 2017. Mr. Collins will serve as an independent director of the company and a member of the board’s Audit Committee.
“As the healthcare industry evolves, continuous glucose monitoring (CGM) will play a vital role in driving cost effective clinical outcomes for patients, providers and payors,” said Terry Gregg, DexCom Executive Chairman. “Rich’s deep industry experience will bring an invaluable perspective to our Board.”
Mr. Collins is currently a Principal at The Pivot Group, an insurance industry consultancy, and brings 30 years of healthcare experience to DexCom. Previously, he spent 17 years at United Healthcare and held numerous key leadership positions during United Healthcare’s transformation into the largest healthcare insurer in the United States. Mr. Collins earned his Bachelor of Science from Maine Maritime Academy.
“DexCom’s market leadership in CGM leaves it well positioned to become a fundamental technology in the management of diabetes, one of the most impactful health conditions of our time,” said Collins. “I am very excited to join the board at this point in the company’s journey.”
About DexCom, Inc.
DexCom, Inc., headquartered in San Diego, CA, is dedicated to helping people better manage their diabetes by developing and marketing continuous glucose monitoring (CGM) products and tools for adult and pediatric patients. With exceptional performance, patient comfort and lifestyle flexibility at the heart of its technology, users have consistently ranked DexCom highest in customer satisfaction and loyalty.
For more information : https://www.dexcom.com
- Disclaimer - News, data, and statements included in this release are intended exclusively for general information purposes. Talent4Boards does not guarantee that news is accurate or about the correct person and accepts neither liability for the consequences of the reader’s reliance, nor responsibility for the accuracy of the information. Nothing in this release should be considered for decisions about referred securities. Products and brand names may be trademarks or registered trademarks of their respective owners.
